Anti-HDV immunoglobulin M testing in hepatitis delta revisited: correlations with disease activity and response to pegylated interferon-alpha 2a treatment


Mederacke I., Yurdaydin C., Dalekos G. N. , Bremer B., Erhardt A., Cakaloglu Y., ...More

ANTIVIRAL THERAPY, vol.17, no.2, pp.305-312, 2012 (Peer-Reviewed Journal) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 17 Issue: 2
  • Publication Date: 2012
  • Doi Number: 10.3851/imp1926
  • Journal Name: ANTIVIRAL THERAPY
  • Journal Indexes: Science Citation Index Expanded, Scopus
  • Page Numbers: pp.305-312

Abstract

Background: The role of anti-HDV immunoglobulin M (IgM) testing in patients receiving pegylated interferon-alpha therapy for hepatitis delta is unknown. We performed anti-HDV IgM testing in a well defined cohort of HDVinfected patients who were treated with pegylated interferon-alpha 2a plus adefovir, or either drug alone.